Organon (OGN) shares surged over 25% on Friday after it was revealed that Sun Pharmaceutical Industries from India has proposed a $13 billion all-cash offer to acquire the women’s health-focused pharmaceutical company.
Acquisition Proposal Details
The Economic Times initially reported the news on Thursday evening, citing sources familiar with the negotiations. Following the announcement, Organon’s stock rose about 8% in after-hours trading and continued to gain momentum throughout Friday.
At the time the reports emerged, Organon was valued at approximately $2.2 billion. The proposed acquisition at $13 billion reflects a remarkable premium compared to its recent trading values.
Significance of the Deal
If finalized, this acquisition would mark the largest in Sun Pharma’s history. The offer is reportedly fully backed by financing commitments from major financial institutions, including JP Morgan, MUFG, and Citi.
Sun Pharma aims to seamlessly integrate Organon into its existing operations, with the proposal designed as an all-cash transaction that does not involve issuing equity to current Organon shareholders.
Competitive Landscape
This marks the second attempt by Sun Pharma to acquire Organon, with earlier reports suggesting a $12 billion bid submitted earlier in the month. The latest proposal represents a significant increase of $1 billion in a short period.
However, Sun Pharma is not alone in its interest. Competing offers have come from Germany’s Grünenthal and the Swedish private equity firm EQT, highlighting the appeal of Organon’s extensive portfolio of women’s health medications, along with its domestic manufacturing capabilities in the U.S.
Organon’s Journey as a Standalone Entity
Organon became an independent company following its spinoff from Merck in June 2021. Since then, the stock has seen fluctuations, declining about 30% over the past year, despite the notable increase on Friday.
The announcement of the potential acquisition ignited a wave of buying activity, with over 5.2 million shares of OGN traded shortly after the opening bell on Friday. This amount was nearly equivalent to the stock’s entire three-month average daily volume of 5.9 million shares, all within the initial hours of trading.
Year-to-Date Performance
The substantial rally of 25.47% on Friday improved Organon’s year-to-date performance to a 20.25% return. OGN shares were trading above $9.20 during after-hours on Thursday, reflecting a significant rebound from its earlier market capitalization of $2.2 billion at the close of the regular session.
Confirmation Status
As of Friday afternoon, neither Sun Pharma nor Organon has provided official confirmation regarding the potential acquisition agreement.
In summary, the proposed acquisition of Organon by Sun Pharma has generated substantial market activity and interest, reflecting the strategic value of Organon’s offerings in women’s health. As negotiations progress, the outcome could significantly reshape the landscape of the pharmaceutical industry focused on women’s healthcare.
Key Takeaways:
- Organon shares jumped over 25% following a $13 billion acquisition proposal from Sun Pharma.
- The offer represents a significant premium over Organon’s market valuation prior to the news.
- Sun Pharma faces competition from other bidders, including Grünenthal and EQT.
- Organon has shown volatility since its spinoff from Merck, despite a recent positive performance.
- Neither company has confirmed the acquisition as of the latest updates.
Read more → blockonomi.com